1-13 of 13
Opeyemi Jegede
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Representation of Minorities in Therapeutic Clinical Trials - a 15-Year Review of Lymphoma Cooperative Group Studies (Alliance A152123)

Alvaro J Alencar, Susan M. Geyer, Electra D Paskett, Levi D. Pederson, Travis Dockter, Nilanjan Ghosh, Kehinde Adekola, Joseph M Unger, Opeyemi Jegede, Jonathan W. Friedberg, Brad S. Kahl, Shira N. Dinner, Nancy L. Bartlett, Kristie A. Blum, John P. Leonard
Journal: Blood
Blood (2024) 144 (Supplement 1): 110.
https://doi.org/10.1182/blood-2024-209365
Published: 2024
Journal Articles

Addition or Substitution of Acalabrutinib in Intensive Frontline Chemoimmunotherapy for Patients ≤ 70 Years Old with Mantle Cell Lymphoma: Outcomes of the 3-Arm Randomized Phase II Intergroup Trial ECOG-ACRIN EA4181

Nina Wagner-Johnston, Opeyemi Jegede, Stephen E Spurgeon, Kami J. Maddocks, David T Yang, Justin Romanoff, Jonas Paludo, Paolo F. Caimi, Nancy L. Bartlett, Patrick M. Reagan, Yazeed Sawalha, Marc Hoffmann, Boyu Hu, Ashraf R Aziz, Helga Marques, Lale Kosakoglu Shields, John P. Leonard, Jonathan W. Friedberg, Brad S. Kahl
Journal: Blood
Blood (2024) 144 (Supplement 1): 236.
https://doi.org/10.1182/blood-2024-194641
Published: 2024
Journal Articles

Safety and Efficacy in Pediatric Patients with Relapsed/Refractory Classic Hodgkin Lymphoma Enrolled on an Intergroup Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin (E4412)

Christopher J. Forlenza, Opeyemi Jegede, Stephen M. Ansell, Christian Steidl, Yasodha Natkunam, David W. Scott, Neha Mehta-Shah, Jennifer E. Amengual, Peter D. Cole, Brad S. Kahl, Catherine S. Diefenbach
Journal: Blood
Blood (2024) 144 (Supplement 1): 4427.
https://doi.org/10.1182/blood-2024-201624
Published: 2024
Journal Articles

Results from an Intergroup Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Classic Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Research Group (E4412)

Catherine S Diefenbach, Opeyemi Jegede, Stephen M Ansell, Christian Steidl, Yasodha Natkunam, David W. Scott, Neha Mehta-Shah, Jennifer E Amengual, Christopher J. Forlenza, Peter D. Cole, Nancy L. Bartlett, Kevin A. David, Ranjana H. Advani, Richard F. Ambinder, Sachdev Thomas, Sami Ibrahimi, Brad S. Kahl
Journal: Blood
Blood (2023) 142 (Supplement 1): 607.
https://doi.org/10.1182/blood-2023-184531
Published: 2023
Journal Articles

Primary Analysis and Results of Bendamustine, Rituximab, and Venetoclax (BR-VEN) for Initial Treatment of Mantle Cell Lymphoma in Subjects over 60 Years of Age (PrE0405)

Craig A. Portell, Opeyemi Jegede, N. Nora Bennani, Seema Naik, Christopher M. Reynolds, Priyank P. Patel, Michael J. Robertson, Brad S. Kahl
Journal: Blood
Blood (2023) 142 (Supplement 1): 733.
https://doi.org/10.1182/blood-2023-182374
Published: 2023
Journal Articles

Immune Landscape Associated with Response to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Relapsed/Refractory Hodgkin Lymphoma (E4412 Phase 1)

Catherine S Diefenbach, Edgar Gonzalez-Kozlova, Diane Marie Del Valle, Hsin-Hui Huang, Opeyemi Jegede, Vanessa Barcessat, Kevin Tuballes, Geoffrey Kelly, Manishkumar Patel, Hui Xie, Jocelyn Harris, Kimberly Argueta, Kai Nie, Radim Moravec, Jennifer Altreuter, Dzifa Yawa Duose, Brad S. Kahl, Stephen M Ansell, Joyce Yu, Ethan Cerami, James Lindsay, Ignacio Wistuba, Seunghee Kim-Schulze, Sacha Gnjatic
Journal: Blood
Blood (2023) 142 (Supplement 1): 4382.
https://doi.org/10.1182/blood-2023-174903
Published: 2023
Journal Articles

Ibrutinib and Ixazomib in Relapsed/Refractory Mantle Cell Lymphoma: Precog 0404

Jonathon B. Cohen, Opeyemi Jegede, Craig A. Portell, Mehdi Hamadani, Catherine S. Diefenbach, Kevin A. David, Christopher D. Fletcher, Daniel J. Landsburg, Suparna Mantha, Brad S. Kahl
Journal: Blood
Blood (2022) 140 (Supplement 1): 6487–6488.
https://doi.org/10.1182/blood-2022-164710
Published: 2022
Journal Articles

Randomized Phase 2 Trial of First-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma ECOG-ACRIN E1411

Mitchell R Smith, Opeyemi Jegede, Peter Martin, Brian G. Till, Samir Parekh, David T. Yang, Lale Kostakoglu, Carla Casulo, Nancy Bartlett, Paolo F Caimi, Tareq Al Baghdadi, Kami J. Maddocks, Mark D. Romer, David J. Inwards, Rachel E. Lerner, Lynne I. Wagner, Richard Little, Jonathan W. Friedberg, John P. Leonard, Brad S. Kahl
Journal: Blood
Blood (2022) 140 (Supplement 1): 186–188.
https://doi.org/10.1182/blood-2022-170381
Published: 2022
Journal Articles

Phase II Study of Venetoclax in Combination with Obinutuzumab and Bendamustine in Patients with High Tumor Burden Follicular Lymphoma As Front Line Therapy (PrECOG 0403)

Craig A. Portell, Opeyemi Jegede, Nina D. Wagner-Johnston, Grzegorz S. Nowakowski, Christopher D. Fletcher, Jonathon B. Cohen, Kevin A. David, Nadia Khan, Lori J Rosenstein, Brad S. Kahl
Journal: Blood
Blood (2021) 138 (Supplement 1): 814.
https://doi.org/10.1182/blood-2021-145217
Published: 2021
Journal Articles

Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma over 60 Years of Age (PrE0405): A Phase II Study

Craig A. Portell, MD, N. Nora Bennani, MD, Opeyemi Jegede, PhD, Seema Naik, MD, Benjamin M Parsons, DO, Priyank P Patel, MD, Christopher M. Reynolds, MD, Brad S. Kahl, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5243.
https://doi.org/10.1182/blood-2019-122759
Published: 2019
Journal Articles

A Phase I/II Study of Ibrutinib and Ixazomib in Relapsed/Refractory Mantle Cell Lymphoma: PrE0404

Jonathon B. Cohen, MDMS, Craig A. Portell, MD, Mehdi Hamadani, MD, Opeyemi Jegede, PhD, Catherine Diefenbach, MD, Kevin A. David, MD, Christopher D. Fletcher, MD, Daniel J. Landsburg, MD, Brad S. Kahl, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1541.
https://doi.org/10.1182/blood-2019-127494
Published: 2019
Journal Articles

Minimal Residual Disease (MRD) Assessment in the ECOG1411 Randomized Phase 2 Trial of Front-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma (MCL)

Mitchell Smith, MD PhD, Opeyemi Jegede, PhD, Samir Parekh, MD, Curtis A. Hanson, MD, Peter Martin, FRCPC, MD MS, Brian G. Till, MD, Michael Crump, MD FRCPC, John P. Leonard, MD, Jonathan W. Friedberg, MD, Brad S. Kahl, MD, Thomas E. Witzig, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 751.
https://doi.org/10.1182/blood-2019-129323
Published: 2019
Journal Articles

The Prognostic Impact of Baseline Positron Emission Tomography (PET) Imaging in Untreated High Risk (HR) Follicular Lymphoma (FL): Analysis from E2408, the Bortezomib Induction or Novel Imid® Continuation (BIONIC) Study

Lucia Baratto, MD, Opeyemi Jegede, PhD, Fangxin Hong, PhD, Thomas M. Habermann, MD, Ranjana Advani, MD, Randy D. Gascoyne, MD, Lale Kostakoglu, MD, Thomas E. Witzig, MD, Erik A. Ranheim, MD PhD, Brad S Kahl, MD, Andrew Quon, MD, Andrew M. Evens, DO, MSc
Journal: Blood
Blood (2018) 132 (Supplement 1): 1615.
https://doi.org/10.1182/blood-2018-99-113247
Published: 2018